DK1459766T3 - Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner - Google Patents
Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vaccinerInfo
- Publication number
- DK1459766T3 DK1459766T3 DK04014973T DK04014973T DK1459766T3 DK 1459766 T3 DK1459766 T3 DK 1459766T3 DK 04014973 T DK04014973 T DK 04014973T DK 04014973 T DK04014973 T DK 04014973T DK 1459766 T3 DK1459766 T3 DK 1459766T3
- Authority
- DK
- Denmark
- Prior art keywords
- polynucleotide
- immune responses
- based vaccines
- adjuvant compositions
- boost immune
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12634099P | 1999-03-26 | 1999-03-26 | |
PCT/US2000/008282 WO2000057917A2 (fr) | 1999-03-26 | 2000-03-24 | Compositions d'adjuvant et methodes permettant d'accentuer les reponses immunitaires a des vaccins a base de polynucleotides |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1459766T3 true DK1459766T3 (da) | 2008-10-13 |
Family
ID=22424291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04014973T DK1459766T3 (da) | 1999-03-26 | 2000-03-24 | Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner |
Country Status (10)
Country | Link |
---|---|
US (7) | US6586409B1 (fr) |
EP (2) | EP1165140B1 (fr) |
JP (2) | JP4800485B2 (fr) |
AT (3) | ATE272410T1 (fr) |
CA (1) | CA2365416C (fr) |
DE (2) | DE60012711T2 (fr) |
DK (1) | DK1459766T3 (fr) |
ES (1) | ES2308069T3 (fr) |
HK (1) | HK1121382A1 (fr) |
WO (1) | WO2000057917A2 (fr) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7105574B1 (en) | 1999-03-26 | 2006-09-12 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
US5641665A (en) * | 1994-11-28 | 1997-06-24 | Vical Incorporated | Plasmids suitable for IL-2 expression |
US20020088014A1 (en) * | 1996-05-31 | 2002-07-04 | Xiangming Fang | Minimal adenovirus mediated recombinant vaccine |
ATE550042T1 (de) * | 1997-11-20 | 2012-04-15 | Vical Inc | Behandlung von krebs mithilfe cytokin- exprimierender polynukleotide und zusammensetzungen dafür |
ES2308069T3 (es) * | 1999-03-26 | 2008-12-01 | Vical Incorporated | Composiciones adyuvantes para realzar inmunorespuestas a las vacunas polinucleotido-basadas. |
US7078388B2 (en) * | 2000-01-21 | 2006-07-18 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
EP1278551A2 (fr) * | 2000-04-21 | 2003-01-29 | Vical Incorporated | Compositions pour l'administration i in vivo /i d'agents therapeutiques derives de polynucleotides et methodes associees |
US20030162733A1 (en) * | 2000-11-27 | 2003-08-28 | Haynes Joel R. | Nucleic acid adjuvants |
GB0210538D0 (en) * | 2002-05-08 | 2002-06-19 | Univ London | Lipids and gene delivery |
US7598421B2 (en) | 2002-05-08 | 2009-10-06 | Ucl Biomedica Plc | Materials for the delivery of biologically-active material to cells |
US20070105799A1 (en) * | 2002-09-10 | 2007-05-10 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against Bacillus anthracis infection |
CA2508228C (fr) | 2002-12-23 | 2013-12-17 | Vical Incorporated | Vaccins a base de polynucleotides a codon optimise diriges contre l'infection par le cytomegalovirus humain |
AU2003293195A1 (en) | 2002-12-23 | 2004-07-29 | Vical Incorporated | Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
JP5390059B2 (ja) * | 2002-12-23 | 2014-01-15 | バイカル インコーポレイテッド | 無菌ポリヌクレオチド系薬剤の製造方法 |
US8080642B2 (en) | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
US7504243B2 (en) | 2004-03-19 | 2009-03-17 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for the production of biliverdin |
US7303881B2 (en) * | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
JP5331340B2 (ja) | 2004-05-18 | 2013-10-30 | バイカル インコーポレイテッド | インフルエンザウィルスワクチン組成物、及びその使用方法 |
WO2005122739A2 (fr) | 2004-06-15 | 2005-12-29 | The New York Blood Center, Inc. | Propriete d'adjuvance et de stimulation des fonctions immunitaires de produits naturels de onchocerca volvulus |
US20060134221A1 (en) * | 2004-12-03 | 2006-06-22 | Vical Incorporated | Methods for producing block copolymer/amphiphilic particles |
US20060177468A1 (en) * | 2005-01-05 | 2006-08-10 | Philadelphia Health and Education Corporation (d/b/a Drexel University College of Medicine | Delivery vehicles, bioactive substances and viral vaccines |
CA2601924A1 (fr) | 2005-02-18 | 2006-08-24 | Novartis Vaccines And Diagnostics, Inc. | Proteines et acides nucleiques provenant de escherichia coli associe a la meningite/septicemie |
WO2006091517A2 (fr) | 2005-02-18 | 2006-08-31 | Novartis Vaccines And Diagnostics Inc. | Immunogenes d'escherichia coli uropathogene |
US7957507B2 (en) | 2005-02-28 | 2011-06-07 | Cadman Patrick F | Method and apparatus for modulating a radiation beam |
CA2604909A1 (fr) | 2005-04-15 | 2006-10-26 | The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services | Procedes et compositions permettant de produire une reponse immunitaire amelioree contre un immunogene papillomavirus humain |
US8232535B2 (en) | 2005-05-10 | 2012-07-31 | Tomotherapy Incorporated | System and method of treating a patient with radiation therapy |
EP1907968A4 (fr) | 2005-07-22 | 2009-10-21 | Tomotherapy Inc | Methode et systeme pour evaluer des criteres d'assurance qualite concernant un programme d'administration de traitement |
EP1906826A4 (fr) | 2005-07-22 | 2009-10-21 | Tomotherapy Inc | Systeme et procede permettant de detecter un cycle respiratoire chez un patient recevant un traitement de radiotherapie |
US8442287B2 (en) | 2005-07-22 | 2013-05-14 | Tomotherapy Incorporated | Method and system for evaluating quality assurance criteria in delivery of a treatment plan |
CA2616304A1 (fr) | 2005-07-22 | 2007-02-01 | Tomotherapy Incorporated | Systeme et methode pour administrer un traitement de radiotherapie a une zone mobile cible |
KR20080039920A (ko) | 2005-07-22 | 2008-05-07 | 토모테라피 인코포레이티드 | 방사선 치료 시스템에 의해 부여되는 선량을 평가하는시스템 및 방법 |
JP5390855B2 (ja) | 2005-07-23 | 2014-01-15 | トモセラピー・インコーポレーテッド | ガントリおよび治療台の協調した動きを利用した放射線療法の撮像およびデリバリー |
WO2007052055A1 (fr) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Vaccins avec adjuvant comprenant des antigenes sans virions prepares a partir de virus influenza eleves en culture cellulaire |
US20090081157A1 (en) | 2006-01-09 | 2009-03-26 | Richard Syd Kornbluth | Immunostimulatory Combinations for Vaccine Adjuvants |
KR20080089663A (ko) | 2006-01-27 | 2008-10-07 | 노바티스 백신즈 앤드 다이아그노스틱스 게엠베하 운트 콤파니 카게 | 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신 |
WO2007110776A1 (fr) | 2006-03-24 | 2007-10-04 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Stockage de vaccins antigrippaux sans refrigeration |
EP2019686B1 (fr) | 2006-03-31 | 2012-07-11 | Novartis AG | Immunisation mucosale et parentérale combinée contre le vih |
DK2054431T3 (da) | 2006-06-09 | 2012-01-02 | Novartis Ag | Konformere af bakterielle adhæsiner |
JP5872755B2 (ja) | 2006-07-20 | 2016-03-01 | バイカル インコーポレイテッド | 抗hsv−2ワクチン接種のための組成物および方法 |
GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
JP2010500399A (ja) | 2006-08-16 | 2010-01-07 | ノバルティス アーゲー | 尿路病原性大腸菌由来の免疫原 |
EP2497495B3 (fr) | 2006-09-11 | 2021-02-17 | Seqirus UK Limited | Fabrication de vaccins contre la grippe sans utiliser d'oeufs |
WO2008127450A2 (fr) * | 2006-12-04 | 2008-10-23 | Vical Incorporated | Vaccins à cassette d'expression linéaire |
ES2480491T3 (es) | 2006-12-06 | 2014-07-28 | Novartis Ag | Vacunas incluyendo antígeno de cuatro cepas de virus de la gripe |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
US8877206B2 (en) * | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
CA2684923C (fr) | 2007-05-02 | 2015-01-06 | Merial Limited | Plasmides a adn a expression et stabilite ameliorees |
US20080274137A1 (en) * | 2007-05-02 | 2008-11-06 | Jean Christophe Francis Audonnet | DNA plasmids having improved expression and stability |
EP2167480A2 (fr) * | 2007-05-23 | 2010-03-31 | Vical Incorporated | Compositions et procédés pour améliorer la réponse immunitaire à des vaccins |
US20090004203A1 (en) * | 2007-05-29 | 2009-01-01 | Vical Incorporated | Methods of treating measles infectious disease in mammals |
WO2009001217A2 (fr) | 2007-06-27 | 2008-12-31 | Novartis Ag | Vaccins antigrippaux à faible teneur en additifs |
GB0713880D0 (en) * | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
ES2712505T3 (es) | 2008-04-17 | 2019-05-13 | Pds Biotechnology Corp | Estimulación de una respuesta inmunitaria por enantiómeros de lípidos catiónicos |
PL2429581T3 (pl) * | 2009-05-14 | 2016-01-29 | Bayer Ip Gmbh | Wzmocniona odpowiedź immunologiczna u gatunków ptaków |
EP4218799A1 (fr) | 2009-07-15 | 2023-08-02 | GlaxoSmithKline Biologicals S.A. | Compositions de protéine f rsv et leurs procédés de fabrication |
EP2575988A1 (fr) | 2010-05-28 | 2013-04-10 | Tetris Online, Inc. | Infrastructure de jeu informatique asynchrone hybride interactif |
US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
JP2013540700A (ja) | 2010-08-09 | 2013-11-07 | サイバツクス・インコーポレイテツド | 病気を予防するための方法および組成物 |
MX345854B (es) | 2010-12-22 | 2017-02-17 | Bayer Ip Gmbh | Respuesta inmune potenciada en la especie bovina. |
EP2667892B1 (fr) | 2011-01-26 | 2019-03-27 | GlaxoSmithKline Biologicals SA | Régime d'immunisation contre le vrs |
PT2707385T (pt) | 2011-05-13 | 2017-12-19 | Glaxosmithkline Biologicals Sa | Antigénios de f de rsv pré-fusão |
US20130071403A1 (en) | 2011-09-20 | 2013-03-21 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
WO2013106558A1 (fr) * | 2012-01-10 | 2013-07-18 | Merial Limited | Adjuvants à base de lipide pour vaccins à adn plasmidiques |
WO2013108272A2 (fr) | 2012-01-20 | 2013-07-25 | International Centre For Genetic Engineering And Biotechnology | Vaccin antipaludique ciblant le stade sanguin |
CN105101991A (zh) | 2012-09-21 | 2015-11-25 | Pds生物科技公司 | 改进的疫苗组合物和使用方法 |
WO2014133849A2 (fr) | 2013-02-26 | 2014-09-04 | Accuray Incorporated | Collimateur multilame actionné par voie électromagnétique |
EP3110940A1 (fr) | 2014-02-28 | 2017-01-04 | Bayer Animal Health GmbH | Plasmides immunostimulateurs |
CN108025062A (zh) | 2015-07-31 | 2018-05-11 | 拜耳动物保健有限责任公司 | 猪科动物物种中增强的免疫应答 |
US11612652B2 (en) | 2015-11-13 | 2023-03-28 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
AU2016367712B2 (en) | 2015-12-09 | 2021-10-07 | Jingang Medicine (Australia) Pty Ltd | Immunomodulating composition for treatment |
CN105483076B (zh) * | 2015-12-23 | 2019-01-25 | 中国科学院生物物理研究所 | 一种脂肪体的制备方法及其应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
US6706694B1 (en) | 1990-03-21 | 2004-03-16 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
US20030186913A1 (en) | 1990-03-21 | 2003-10-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
US6228844B1 (en) | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US7105574B1 (en) * | 1999-03-26 | 2006-09-12 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
US5910488A (en) | 1993-06-07 | 1999-06-08 | Vical Incorporated | Plasmids suitable for gene therapy |
IL113817A (en) | 1994-06-30 | 2001-03-19 | Merck & Co Inc | Polynucleotide for vaccination against the umbilical cord virus |
US5641665A (en) | 1994-11-28 | 1997-06-24 | Vical Incorporated | Plasmids suitable for IL-2 expression |
IL122290A0 (en) | 1995-06-07 | 1998-04-05 | Inex Pharmaceuticals Corp | Lipid-nucleic acid complex its preparation and use |
US5705385A (en) * | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
CA2237316C (fr) * | 1995-11-30 | 2012-06-26 | Vical Incorporated | Lipides cationiques complexes |
US5994317A (en) | 1996-04-09 | 1999-11-30 | Vical Incorporated | Quaternary cytofectins |
US5861397A (en) | 1996-10-03 | 1999-01-19 | Vical Incorporated | Piperazine based cytofectins |
US6235310B1 (en) * | 1997-04-04 | 2001-05-22 | Valentis, Inc. | Methods of delivery using cationic lipids and helper lipids |
ATE550042T1 (de) * | 1997-11-20 | 2012-04-15 | Vical Inc | Behandlung von krebs mithilfe cytokin- exprimierender polynukleotide und zusammensetzungen dafür |
ES2308069T3 (es) | 1999-03-26 | 2008-12-01 | Vical Incorporated | Composiciones adyuvantes para realzar inmunorespuestas a las vacunas polinucleotido-basadas. |
US6696424B1 (en) | 1999-05-28 | 2004-02-24 | Vical Incorporated | Cytofectin dimers and methods of use thereof |
EP1278551A2 (fr) | 2000-04-21 | 2003-01-29 | Vical Incorporated | Compositions pour l'administration i in vivo /i d'agents therapeutiques derives de polynucleotides et methodes associees |
WO2002072019A2 (fr) | 2001-03-13 | 2002-09-19 | Vical Incorporated | Therapie par polynucleotide codant un interferon-beta pour des maladies auto-immunes et inflammatoires |
US8709550B2 (en) | 2002-01-28 | 2014-04-29 | Jfe Steel Corporation | Method for producing coated steel sheet |
US20070105799A1 (en) * | 2002-09-10 | 2007-05-10 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against Bacillus anthracis infection |
AU2003293195A1 (en) | 2002-12-23 | 2004-07-29 | Vical Incorporated | Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
CA2508228C (fr) | 2002-12-23 | 2013-12-17 | Vical Incorporated | Vaccins a base de polynucleotides a codon optimise diriges contre l'infection par le cytomegalovirus humain |
JP5390059B2 (ja) | 2002-12-23 | 2014-01-15 | バイカル インコーポレイテッド | 無菌ポリヌクレオチド系薬剤の製造方法 |
US8080642B2 (en) * | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
-
2000
- 2000-03-24 ES ES04014973T patent/ES2308069T3/es not_active Expired - Lifetime
- 2000-03-24 EP EP00919777A patent/EP1165140B1/fr not_active Expired - Lifetime
- 2000-03-24 EP EP08006254A patent/EP1955709B1/fr not_active Expired - Lifetime
- 2000-03-24 AT AT00919777T patent/ATE272410T1/de not_active IP Right Cessation
- 2000-03-24 JP JP2000607666A patent/JP4800485B2/ja not_active Expired - Fee Related
- 2000-03-24 WO PCT/US2000/008282 patent/WO2000057917A2/fr active Search and Examination
- 2000-03-24 CA CA2365416A patent/CA2365416C/fr not_active Expired - Fee Related
- 2000-03-24 AT AT08006254T patent/ATE549032T1/de active
- 2000-03-24 DE DE60012711T patent/DE60012711T2/de not_active Expired - Lifetime
- 2000-03-24 US US09/534,943 patent/US6586409B1/en not_active Expired - Lifetime
- 2000-03-24 DK DK04014973T patent/DK1459766T3/da active
- 2000-03-24 AT AT04014973T patent/ATE397942T1/de active
- 2000-03-24 DE DE60039198T patent/DE60039198D1/de not_active Expired - Fee Related
-
2003
- 2003-03-19 US US10/391,216 patent/US7582613B2/en not_active Expired - Fee Related
-
2007
- 2007-03-23 JP JP2007075889A patent/JP2007176954A/ja not_active Withdrawn
- 2007-08-17 US US11/889,980 patent/US20080213306A1/en not_active Abandoned
- 2007-08-17 US US11/889,977 patent/US20080145387A1/en not_active Abandoned
-
2009
- 2009-02-11 HK HK09101261.1A patent/HK1121382A1/xx not_active IP Right Cessation
-
2011
- 2011-02-18 US US13/031,064 patent/US8415317B2/en not_active Expired - Fee Related
-
2013
- 2013-03-13 US US13/802,535 patent/US20140065189A1/en not_active Abandoned
- 2013-03-13 US US13/802,567 patent/US20130295139A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2000057917A3 (fr) | 2001-01-04 |
JP4800485B2 (ja) | 2011-10-26 |
HK1121382A1 (en) | 2009-04-24 |
US20130295139A1 (en) | 2013-11-07 |
ATE397942T1 (de) | 2008-07-15 |
EP1955709A3 (fr) | 2008-08-20 |
US20080213306A1 (en) | 2008-09-04 |
US20030191082A1 (en) | 2003-10-09 |
JP2002540173A (ja) | 2002-11-26 |
EP1165140A2 (fr) | 2002-01-02 |
US20080145387A1 (en) | 2008-06-19 |
CA2365416C (fr) | 2011-06-14 |
ES2308069T3 (es) | 2008-12-01 |
WO2000057917A2 (fr) | 2000-10-05 |
US20140065189A1 (en) | 2014-03-06 |
EP1165140B1 (fr) | 2004-08-04 |
EP1955709B1 (fr) | 2012-03-14 |
CA2365416A1 (fr) | 2000-10-05 |
US6586409B1 (en) | 2003-07-01 |
US7582613B2 (en) | 2009-09-01 |
JP2007176954A (ja) | 2007-07-12 |
US8415317B2 (en) | 2013-04-09 |
DE60012711T2 (de) | 2005-08-18 |
DE60012711D1 (de) | 2004-09-09 |
ATE272410T1 (de) | 2004-08-15 |
US20110165197A1 (en) | 2011-07-07 |
ATE549032T1 (de) | 2012-03-15 |
EP1955709A2 (fr) | 2008-08-13 |
DE60039198D1 (de) | 2008-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1459766T3 (da) | Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner | |
NO20023829D0 (no) | Proteosom influensavaksine | |
IS4518A (is) | Nýtt lyfjaform fyrir bóluefni | |
DK1104306T3 (da) | Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf | |
DK1147117T3 (da) | Immunologiske adjuvansforbindelser | |
DK1487485T3 (da) | Imidazoquinolinadjuvanser til DNA-vacciner | |
ATE426412T1 (de) | Adjuvante influenza-vakzine | |
GB2386072A (en) | Novel vaccine | |
BR0111834A (pt) | Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno | |
DK1259259T3 (da) | Mucosal adjuvansformulering | |
AU2001284354A1 (en) | Immunological adjuvant compounds, compositions, and methods of use thereof | |
ATE284613T1 (de) | Polynukleotid-impfstoff-formulierungen | |
DE69637435D1 (de) | Saponin-zusammensetzungen und deren verwendung | |
ATE353226T1 (de) | Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form | |
DK1227840T3 (da) | Adjuverede, genetiske vacciner | |
DE69942161D1 (de) | Genetische Adjuvanz-Impfstoffe | |
EP1721618A3 (fr) | Composition de Proteasome pour la vaccination antigrippale |